Neurocrine Biosciences
NBIX
#1347
Rank
NZ$28.41 B
Marketcap
NZ$282.64
Share price
-2.07%
Change (1 day)
35.43%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): NZ$11.51

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is NZ$11.57. In 2025 the company made an earnings per share (EPS) of NZ$8.31 an increase over its 2024 EPS that were of NZ$5.83.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$11.5138.47%
2025NZ$8.3142.6%
2024NZ$5.8333.07%
2023NZ$4.3857.76%
2022NZ$2.7869.47%
2021NZ$1.64-78.21%
2020NZ$7.52990%
2019NZ$0.6981.82%
2018NZ$0.38-113.5%
2017NZ-$2.810.62%
2016NZ-$2.7957.28%
2015NZ-$1.7825.61%
2014NZ-$1.4118.84%
2013NZ-$1.19-1085.71%
2012NZ$0.12

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.26-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$3.55-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.68 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
NZ$1.59-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
NZ-$3.50-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$6.04-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
NZ-$51.57-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$3.28-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK